Jump to content

Search the Community

Showing results for tags 'Metastatic'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • COMMUNITY
    • Announcements, meetings and other resources
  • ADVANCED PROSTATE CANCER FORUMS
    • Primary hormone therapy
    • Secondary hormone therapy
    • Castrate Resistant Prostate Cancer
    • Metastatic
    • Very high risk
    • New agents
    • Every little bit helps
    • Radiation, diagnostic imaging, bones and other prostate cancer topics
    • Articles on other sites
  • MEMBER'S STORIES AND NEEDS
    • My story
    • Any suggestions?
    • The lounge

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Found 13 results

  1. Hi Guys, No doubt many of you are aware of the recently released results of the Latitude study. I saw my medical oncologist today and when I asked her about we Aussie's having access to Abiraterone, she said that it is not available through the PBS. I'm not sure if she meant under any circumstances, or just early, before castrate resistance. Does anyone else know if this is the case, or how long it might take to become available here? Cheers Paul
  2. 5 Minutes. Cc. Mal and Alison have some beautiful words from Alison to help them deal with life's problems in this short video. One of life's little problems is that Mal has had prostate cancer for 11 years, the past 5 years metastatic. He has had some problems with another medical condition, but no symptoms from his prostate cancer. Many thanks to Mal and Alison who us a glimpse of their private life in order to help others. Jim's twelve year old grandson Matthew McKewin shot all the location shots in this video. Grandpa is very proud. Our YouTube Channel: youtube.com/c/JimJimJimJim People who subscribe to our YouTube channel get to see our videos a little before others. Almost all our videos have Closed Captions Cc for the hard of hearing.
  3. Guihan

    "It must have gone metastatic"

    Nearly 3 years after my Gleason 6 diagnosis and radical prostatectomy, my PSA started to rise again. My urologist (not a cancer specialist) pronounced that “it must have gone metastatic”. (Did he really know, or was this merely a hunch?) I have been on intermittent ADT (one nominally 3-month insert every six months) for over 9 years. My PSA remains too low to record, and I am unaware of any particular side effects. I am delighted with this outcome, but I keep wondering about this “metastatic” label. On the other hand, if it is not metastatic, then what is it, and where is it? It raises the basic question: is a urologist really qualified to declare a prostate cancer as being metastatic?
  4. Treatment of metastatic prostate cancer has changed recently. In the past doctors used to use hormone therapy (ADT) at first, then wait until the disease was very progressed before giving chemotherapy with Taxotere (Docetaxel). The reason for the change? Professor Christopher Sweeney reported on a trial he led (CHAARTED). In CHAARTED, the researchers (an international team of medical oncologists) showed that starting BOTH chemotherapy and ADT at the beginning of treatment gave men a longer life. Yesterday (Sunday, 4 Sep 2016), members of your Executive Committee were invited to be the audience for an video interview of Christopher Sweeney and his Australian colleague, Professor Gavin Marx, by Anthony Lowe, PCFA CEO. Tony Maxwell, Alan Barlee and Nev Black and I were able to attend. (Paul Hobson had to miss out because of treatment.) Being able to question world leaders in advanced prostate cancer treatment was a privilege, and we were able to ask several questions men have raised with us in the past. I have been offered first cut of the video footage. I hope to be able to produce two YouTube videos - one the expert interview, the other on key questions men ask about chemo. Watch this space!
  5. I just noticed that our YouTube video "David's Story" hit 1,000 views today. More than seven and a half years ago David was diagnosed with metastatic prostate cancer. David tells the story of his journey over those years. Many thanks to David for helping so many men and the people who care about them.
  6. Researchers at the University of Santa Cruz and UCLA have developed a new analysis of the genetics and the protein expression of cells involved in metastatic prostate cancer. The goal will be to turn a research tool like this into something that is readily accessible for oncologists and their patients. Click here to read more about this study. [Warning; this article is fairly technical.]
  7. This may be a drug to watch in the future. Seviteronel (VT-464) is a once-daily oral therapeutic given without prednisone. Seviteronel selectively inhibits CYP17 lyase, a target of abiraterone, and has unique blocking effects on the androgen receptor (AR), the target of enzalutamide. There is a growing body of preclinical and clinical evidence that shows that some abiraterone- or enzalutamide-resistant patients will respond to seviteronel treatment. Currently there are phase II clinical trials of seviteronel in the US and Europe. At the moment there are not any clinical trials of this drug in Australia. In January 2016 the United States Food and Drug Administration (FDA) granted Fast Track Designation for seviteronel for the treatment of patients with metastatic castrate-resistant prostate cancer. The Fast Track program is designed to facilitate the development and review of drugs intended to treat serious conditions and fill an unmet medical need.
  8. The New Prostate Cancer Infolink has an article about the announcement of a new clinical trial of Enzalutamide (brand name Xtandi) in men with metastatic, hormone-sensitive prostate cancer. This trial will be recruiting men In Australia. The New Prostate Cancer Infolink expresses concern about the suitability of this trial for men newly diagnosed with a significant presence of metastatic disease. Click on this link to read the article.
  9. The New Prostate Cancer Infolink reports Full data on ADT + chemotherapy from the STAMPEDE trial now published The report has links to the full text of articles in the Lancet regarding this research. "For men with metastatic prostate cancer starting [androgen deprivation] therapy for the first time, we found strong evidence to support the addition of docetaxel to androgen deprivation therapy as the new standard of care, and this combination should be offered to men who are fit to receive chemotherapy. " There is no sufficient evidence yet to recommend docetaxel plus androgen deprivation therapy for hormone-naive men men diagnosed with micrometastatic prostate cancer (cancer in the lymph nodes but not yet metastasised to the bone - M0)
  10. The Prostate Cancer Foundation of Australia has posted a video on YouTube of the following talk on Metastatic Prostate Cancer given by medical oncologist A/Prof Gavin Marx at Sydney Adventist Hospital on 25 May 2015.
  11. Thanks to Chuck Maack for alerting us to this. A collaboration between leading US and British Cancer Centres has been described as a landmark study. Click on this link to read a report of the study. Chuck's comment This appears to be terrific news. The problem now is whether or not the researchers get fast-track funding to continue their research to determine which medications currently are correct for which genomic defects, and what medications are available and might be used singularly or in combination with other medications to go after the other genomic defects. Then…and we don’t know when…we are going to need government approval for coverage for the gene testing that will permit Medicare to cover that expense..... And (another) then, we will need FDA approval (in Australia, TGA approval) for those medications not yet developed/determined or approved for prostate cancer, but now necessary, as well as may need combining with other medications. So, it looks like now it will be a matter of time and how fast-track they continue this research.
  12. A well researched article (pub. online 8 Jan. 2015) by Dr.Michael Kolodziej, MD, FACP in AJMC, (with free access via PubMed,) outlines the current treatment options, as well as those being investigated. http://www.ajmc.com/journals/supplement/2014/ACE021_Dec14_Prostate_CE/ACE021_Dec14_ProstateCE_Kolodziej/ Interestingly, although it covers some of the newer PSMA scanning technology (including C11 Choline) still no mention of the Gallium 68 PSMA scans now available in most? Australian capital cities. Perhaps we lead the USA in this regard?
×